TIGIT and acute myeloid leukemia: TIGIT and PVRIG were increasingly expressed by the CD56dimCD16+ subpopulation in the PB and BM from patients with AML (for TIGIT: p = 0.0004, p < 0.0001; and for PVRIG: p = 0.0078, p < 0.0001; Figure 3), whereas the expression of CD39 and CD38 was significantly upregulated on the CD56brightCD16− cells in AML-derived PB and BM in comparison to the HD-derived PB (for CD39: p = 0.08, p < 0.0001; and for CD38: p = 0.07, p = 0.0030; Figure 3).